Peritoneal Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's, "Peritoneal Cancer Pipeline Insight 2025" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peritoneal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Peritoneal cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Peritoneal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Peritoneal cancer Pipeline Report

* On 19 August 2025, AbbVie announced a study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms.
* On 15 August 2025, Merck Sharp & Dohme LLC conducted a study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
* On 13 August 2025, Imunon organized a phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone. The chemotherapy (NACT & adjuvant) will be a standard regimen of carboplatin + paclitaxel administered every three weeks for a total of 7-9 cycles.
* DelveInsight's Peritoneal Cancer Pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for Peritoneal Cancer treatment.
* The leading Peritoneal Cancer Companies such as Corcept Therapeutics, Eisai Inc, Mersana Therapeutics, Aurealis Therapeutics, K-Group, Beta, Inc., Regeneron Pharmaceuticals, Toray Industries, Inc., TORL Biotherapeutics, LLC, Sutro Biopharma, Inc., Volastra Therapeutics, Inc., Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd., Oncoinvent AS, CanariaBio Inc., OncoC4, Inc., Numab Therapeutics AG, Bristol-Myers Squibb, Medicenna Therapeutics, Inc., MacroGenics and others
* Promising Peritoneal Cancer Pipeline Therapies such as Avastin, Docetaxel, BIBF 1120, epothilone b, Trabectedin, DOXIL, Dexamethasone, Bevacizumab, CP-547,632, Paclitaxel , and others.

Stay ahead with the most recent pipeline outlook for Peritoneal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Peritoneal Cancer Treatment Drugs [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Peritoneal Cancer Emerging Drugs Profile

* Relacorilant: Corcept Therapeutics

Relacorilant is a selective glucocorticoid receptor (GR) modulator currently under investigation for its potential role in treating various cancers, including peritoneal cancer. It works by blocking the activity of cortisol at the glucocorticoid receptor, which can help overcome cortisol-mediated resistance to chemotherapy and immunotherapy often seen in solid tumors. In peritoneal cancer, particularly high-grade serous carcinomas or cancers with peritoneal metastases, Relacorilant may enhance the efficacy of chemotherapeutic agents like nab-paclitaxel by sensitizing tumor cells to treatment. Early clinical studies have shown promising results in improving progression-free survival in certain patient populations, but further trials are ongoing to validate its safety and effectiveness in peritoneal malignancies. Currently, the drug is in Phase III stage of its development for the treatment of Peritoneal Cancer.

* Farletuzumab ecteribulin: Eisai Inc

FZEC is Eisai's first antibody drug conjugate (ADC) and that is composed of Eisai's in-house developed farletuzumab, a humanized IgG1 monoclonal antibody that binds to the folate receptor alpha (FR), and Eisai's in-house developed anticancer agent eribulin, using an enzymatically cleavable linker. After FZEC enters the target FR-positive cancer cells, it is thought that the linker is enzymatically cleaved, releasing eribulin from the antibody leading to its antitumor activity. When the anticancer agent and antibody components of an ADC are separated inside a targeted antigen-positive cancer cell, it is theorized that the released anticancer agent also has a bystander effect on neighboring antigen-negative cancer cells and the component cells of the tumor microenvironment. In pre-clinical studies, FZEC demonstrated a bystander effect, with antitumor activity on the FR-negative cancer cells surrounding the FR-positive cancer cells. The payload eribulin was the first in the halichondrin class of microtubule dynamics inhibitor. Currently, the drug is in Phase II stage of its development for the treatment of Peritoneal Cancer.

* XMT-1660: Mersana Therapeutics

XMT-1660 is a novel DAR-6 Dolasynthen-based antibody drug conjugate carrying a DolaLock payload with controlled bystander effect and targeting B7-H4, a tumor antigen that is broadly expressed on the cell surface in breast, ovarian and endometrial cancers. B7-H4 (VTCN1) exerts immunosuppressive effects by suppression of T cell proliferation and is expressed on tumor-associated macrophages (TAMs) as well as epithelial tumor cells. XMT1660 is comprised of an anti-B7-H4 antibody site-specifically conjugated to Dolasynthen, with a total of 6 DolaLock Auristatin F-HPA (AF-HPA) anti-tubulin payloads per antibody (DAR-6). Currently, the drug is in Phase I stage of its development for the treatment of Peritoneal Cancer.

* AUP-55: Aurealis Therapeutics

AUP-55 is built on a non-pathogenic lactic acid bacteria Lactococcus cremoris that is genetically modified to synthetize Human Interferon Alpha (h-IFN- ), Human Interleukin 15 (h-IL-15) and Endogenous Bacterial Factors TLR2, NOD2 and TLR9. Due to the unique combination of therapeutic proteins, delivered through intra-tumoral injections, AUP-55 is able to activate the innate immune system, activate the adaptive immune system, block angiogenesis, and have a direct tumor killing effect. Currently, the drug is in Preclinical stage of its development for the treatment of Peritoneal Cancer.

The Peritoneal Cancer Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Peritoneal Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peritoneal Cancer Treatment.
* Peritoneal Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Peritoneal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peritoneal Cancer market

Explore groundbreaking therapies and clinical trials in the Peritoneal Cancer Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Peritoneal Cancer Drugs [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Peritoneal Cancer Companies

Corcept Therapeutics, Eisai Inc, Mersana Therapeutics, Aurealis Therapeutics, K-Group, Beta, Inc., Regeneron Pharmaceuticals, Toray Industries, Inc., TORL Biotherapeutics, LLC, Sutro Biopharma, Inc., Volastra Therapeutics, Inc., Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd., Oncoinvent AS, CanariaBio Inc., OncoC4, Inc., Numab Therapeutics AG, Bristol-Myers Squibb, Medicenna Therapeutics, Inc., MacroGenics and others.

Peritoneal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Peritoneal Cancer Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Unveil the future of Peritoneal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Peritoneal Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Peritoneal Cancer Pipeline Report

* Coverage- Global
* Peritoneal Cancer Companies- Corcept Therapeutics, Eisai Inc, Mersana Therapeutics, Aurealis Therapeutics, K-Group, Beta, Inc., Regeneron Pharmaceuticals, Toray Industries, Inc., TORL Biotherapeutics, LLC, Sutro Biopharma, Inc., Volastra Therapeutics, Inc., Seagen, a wholly owned subsidiary of Pfizer, RemeGen Co., Ltd., Oncoinvent AS, CanariaBio Inc., OncoC4, Inc., Numab Therapeutics AG, Bristol-Myers Squibb, Medicenna Therapeutics, Inc., MacroGenics and others.
* Peritoneal Cancer Pipeline Therapies- Avastin, Docetaxel, BIBF 1120, epothilone b, Trabectedin, DOXIL, Dexamethasone, Bevacizumab, CP-547,632, Paclitaxel , and others.
* Peritoneal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Peritoneal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Peritoneal Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Peritoneal Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/peritoneal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Peritoneal cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Peritoneal cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Relacorilant: Corcept Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Farletuzumab ecteribulin: Eisai Inc
* Early Stage Products (Phase I)
* XMT-1660: Mersana Therapeutics
* Preclinical and Discovery Stage Products
* AUP-55: Aurealis Therapeutics
* Inactive Products
* Peritoneal cancer Key Companies
* Peritoneal cancer Key Products
* Peritoneal cancer- Unmet Needs
* Peritoneal cancer- Market Drivers and Barriers
* Peritoneal cancer- Future Perspectives and Conclusion
* Peritoneal cancer Analyst Views
* Peritoneal cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peritoneal-cancer-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peritoneal-cancer-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.